Introduction c-kit is a proto-oncogene encoding a transmembrane tyrosine kinase receptor, CD117, that is structurally related to the platelet-derived growth factor receptor and the receptor for colony-stimulating factor-1 (Yarden et al., 1987) . During development and adulthood, c-kit modulates a number of different processes, including survival, proliferation, migration, homing, and differentiation of hematopoietic cells, germ cells, and cells derived from the neural crest (Lev et al., 1994) . The c-kit receptor is activated by binding a specific ligand, stem cell factor (SCF), which occurs in two alternatively spliced forms (Huang et al., 1992) . While the soluble form immediately stimulates tyrosine kinase activity, the membrane-bound form accounts for longterm effects by enhancing stability of the c-kit receptor and preventing rapid downregulation (Miyazawa et al., 1995) .
c-kit is physiologically expressed in tissue mast cells, germ cells, melanocytes, interstitial cells of Cajal, breast and sweat gland epithelium, and basal cells of the skin (Maeda et al., 1992; Lammie et al., 1994; Tsuura et al., 1994; Robinson et al., 2001) . In addition, a number of tumors express c-kit. This phenotype, for instance, is characteristic for gastrointestinal stromal tumors (Kindblom et al., 1998) and angioleiomyolipomas (Makhlouf et al., 2002) , frequent in small-cell lung carcinomas (Tsuura et al., 1994) , seminomas/dysgerminomas (Tsuura et al., 1994) , and leukemias (Schwartz et al., 1999) , less common in malignant melanomas and breast and ovarian cancers (Arber et al., 1998) , and rare in soft tissue sarcomas (Hornick and Fletcher, 2002) and pediatric solid tumors (Smithey et al., 2002) .
An expression of the c-kit receptor was variously described in neuroblastoma. In vitro studies of cell lines with a view towards elucidating the function of c-kit in neuroblasts nevertheless produced controversial results (Cohen et al., 1994; Beck et al., 1995; Timeus et al., 1997) . We chose to approach this issue by correlating c-kit expression to the clinical outcome in a large representative cohort of neuroblastoma patients (Krams et al., 2002 (Krams et al., , 2003 with long-term follow-up. We will show that c-kit expression is closely associated with differentiation in neuroblastoma, and that it significantly and independently indicates a favorable course of the disease.
Patients and methods

Patients
The cohort under investigation consisted of 161 patients enrolled in the German Neuroblastoma Trial, who were diagnosed between 1983 and 1999. This subset is representative of the totality of patients in the trial, as shown in earlier studies (Krams et al., 2002 (Krams et al., , 2003 . Informed consent for inclusion in this study had been obtained from the parents. In all, 78 of the patients were males and 83 were females. Their median age at diagnosis was 15 months (range 0-191 months). The clinical stage of the disease was evaluated according to the International Neuroblastoma Staging System (INSS) , with the following results: 16 patients (10%) were in stage 1; 21 patients (13%) in stage 2; 41 patients (25%) in stage 3; 55 patients (34.5%) in stage 4, and 28 patients (17.5%) in stage 4S (special). Patients were treated according to the guidelines established by the German Neuroblastoma Trial (NB85, NB90, NB95-S, and NB97), with stratification criteria according to defined risk groups as described elsewhere (Berthold et al., 1997) . In each risk group, patients were treated uniformly. In total, 29 patients had been treated with chemotherapy prior to biopsy. The median follow-up period was 128.3 months (6-251.1 months).
For histological typing and grading, the International Neuroblastoma Pathology Classification (INPC) (Shimada et al., 1999) was applied. Since the INPC system is valid exclusively for biopsy specimens taken before treatment, it could only be employed in 132 cases. These comprised 101 neuroblastomas (31 undifferentiated, 32 poorly differentiated, and 38 differentiating), 29 ganglioneuroblastomas (eight nodular and 21 intermixed), and two ganglioneuromas. Of these 132 cases 69 (52.3%), were with favorable, and 63 (47.7%) with unfavorable histology.
Assessment of c-kit expression
Immunohistochemistry Expression of the c-kit gene protein product was detected immunohistochemically on paraffin sections as described before , using anti-human c-kit (DAKO, Glostrup, Denmark; Code No. A4502, diluted 1 : 50) . No antigen retrieval technique was used. A cross section of human small intestine was carried with each staining series as a positive control, a negative control being obtained by omission of the primary antibody. Mast cells served as internal positive controls and as a reference for positive immunolabeling.
Immunolabeling for c-kit was evaluated in a simpleblind trial fashion by two independent observers (MK and PR). In each case, the entire cut surface of the tumor was scrutinized for positive cells. The overall interobserver concordance was kappa ¼ 0.88. Cases with discordant classification were re-examined, and a consensus was reached. The results remained reproducible when the sections were re-examined up to five times at several days interval.
Quantitative RT-PCR Quantitative RT-PCR for c-kit mRNA from the snap-frozen tissue was performed as described earlier (Krams et al., 2001) . c-kit mRNA was reverse-transcribed, and the cDNA was amplified using the primers kit1 (5 0 -attttctctgcgttctgctcctac-3 0 ), corresponding to GenBank positions 47-70, and kit2 (5 0 -gcccacgcggactattaagtctgat-3 0 ), corresponding to positions 150-174 (GenBank accession no. X06182). This yields a 128 bp amplificate from exons 1 and 2 of the kit gene, which are separated by two introns corresponding to 37 429 bp. The sequence was chosen because no mutations have been described in this region so far, and the correct size of the PCR product excludes accidental amplification of DNA. For quantification, the ubiquitous EWS mRNA was amplified in parallel using primers EWS1 (5 0 -gatgtcagctatacccaggc-3 0 ) corresponding to positions 188-207 and EWS2 (5 0 -gccatatg cagactgagct-3 0 ) corresponding to positions 382-364 (GenBank accession no. X66899). Validation of PCR products was obtained by automated sequencing (ABIprism 310, Perkin-Elmer). c-kit gene transcripts were quantified using a real-time fluorogenic detection system and the Light Cycler quantitation software (Roche Diagnostics), by comparison with serial dilutions of tissue from a gastrointestinal stromal tumor with a known c-kit gain-of-function mutation (deletion in exon 11) after standardization on EWS gene expression.
Mutation screening Genomic DNA was isolated from 40 neuroblastoma cases comprising tumors with strong, moderate or absent c-kit immunoexpression. Tissue sections were deparaffinized, rehydrated, and digested overnight using proteinase K (Roche Molecular Biochemicals). An aliquot (100 ng) was used for PCRmediated amplification of a fragment of exon 11 using a 5 0 Fam-labeled forward primer (5 0 -atttttccctttctccccac 3 0 ) and a reverse primer (gcccctgtttcatactgacc). Samples were transferred to a thermocycler for 35 cycles of PCR amplification (30 s at 951C, 30 s at 501C, and 1 min at 721C), with a final elongation step of 5 min at 721C. PCR products were then analysed by capillary electrophoresis (AbiPrism 310, Applied Biosystems, Langen, Germany).
Western blot analysis Western blot experiments were performed as described before (Sipos et al., 2002) . c-kit was detected using polyclonal rabbit anti-c-kit antibody (A4502, DAKO Japan, Kyoto, Japan) in a concentration of 0.4 mg/ml, with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (81-6120, Zymed, San Francisco, CA, USA) as secondary antibody. The blots were developed with Western blotting detection reagent ECL (Amersham Pharmacia Biotech, Buckinghamshire, UK) and autoradiographed onto a BIOMAX MR film (EASTMAN KODAK Company, Rochester, NY, USA). The quantity and the quality of the loaded samples were controlled by detection of bactin (A 5441, Sigma, Taufkirchen, Germany). Tissue lysates from a gastrointestinal stromal tumor with strong c-kit immunoreactivity served as a positive control, the primary antibody being omitted for negative control.
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MYCN amplification analysis
MYCN copy number was assessed by Southern blot analysis of EcoRI-digested tumor DNA and hybridization with a probe complementary to the MYCN gene (AppligeneOncor, Illkirch, France), or by fluorescence in situ hybridization on paraffin-embedded specimens, as described before (Krams et al., 2002) . A tumor was considered to be MYCN-amplified if more than five gene copies were present, or if tumor nuclei showed large clumped signals, compared with fibroblasts or lymphocytes, which usually showed a pair of distinct nuclear signals. To adjust for potential hyperploidy, samples were cohybridized with a chromosome 2 centromeric probe (AppligeneOncor).
Statistics
All calculations were made using the SPSS software package, version 10.0.5, run on a PC computer. The analyses were conducted on the series of 155 cases for which complete data sets were available, with the exception of the INPC grade, which was assessable in 132 cases. w 2 statistics was used to correlate the categorical variables. Categories of continuous variables were compared by means of the Mann-Whitney U-test and the Kruskal-Wallis nonparametric analysis of variance. The clinical outcome was analysed as eventfree survival (EFS) based on any clinical evidence of relapse or disease progression, or death in the presence of extensive tumor load, which is standard for neuroblastoma. Univariate survival analysis was computed by means of the Kaplan-Meier method, and significance levels were assessed by means of the log-rank test. Patient age was dichotomized with a cutoff point at 1.5 years (Joshi et al., 1992) .
Parameters shown by univariate analysis to be significant were further compared by means of a multivariate Cox regression analysis for multiple proportional hazards using a stepwise (backward as well as forward) conditional approach. The selection of independent factors was achieved with use of the maximum likelihood ratio. Multivariate models were built on the entire cohort (excluding INPC grade as a covariate), and on the 132 cases graded according to the INPC. All P-values are two-sided.
Results
Immunostaining for the c-kit receptor was assessable in 155 tumors. The staining reaction was mostly homogeneously cytoplasmic, with a slight accentuation at the cell membranes. Although the intensity of immunostaining showed some degree of intertumoral and intratumoral variability, the distribution of positive cells was homogeneous in individual tumors. Any unequivocal labeling in more than 10% of the cells was considered a positive reaction. As a rule, however, more than 50% of the tumor cells were labeled in positive cases. A few tumors containing single-scattered reactive cells (less than 5% of the tumor cell population) were classified as negative. In this way, c-kit expression was found in 50 of the 155 tumors (32.3%). In ganglioneuroblastomas and ganglioneuromas, immunoreactivity was restricted to neuroblasts and immature or mature ganglion cells, whereas Schwann cells were consistently negative.
In the analysis of fresh tissue samples, immunopositive tumors contained c-kit mRNA transcripts roughly in proportion to the intensity of immunolabeling and the percentage of positive cells (Figure 1) . Immunonegative tumors were either negative by RT-PCR, or contained low levels of c-kit mRNA. Western blot analysis revealed a specific signal in all, but one, of the immunopositive tumors, with an intensity roughly paralleling the immunolabeling pattern (Figure 1) . No signal was detected in the immunonegative tumors. Capillary electrophoresis consistently showed a single peak corresponding to a 168 bp amplificate of exon 11 of the c-kit gene in both immunopositive and immunonegative tumors, revealing neither deletions nor insertions in this domain.
c-kit expression was unrelated to gender (P ¼ 0.69) and the patients' age at diagnosis (P ¼ 0.59). Cytotoxic treatment prior to biopsy did not appear to affect c-kit expression (P ¼ 0.32). Conversely, c-kit expression was correlated to INSS stage (P ¼ 0.010), with a preponderance in lower tumor stages. c-kit-positive tumors also displayed a lower rate of MYCN gene amplifications (P ¼ 0.011), which were detected in 42 (27.1%) of our cases. The most striking association was nevertheless observed between c-kit expression and incipient or advanced differentiation (Po0.0001, Table 1 ). In accordance, there was also a positive correlation of c-kit expression with INPC favorable histology (P ¼ 0.002).
In the univariate analysis, EFS was found to depend on patient age 41.5 years (relative risk (RR) 2.21, P ¼ 0.002), MYCN amplification (RR 3.21, Po0.0001), INPC unfavorable histology (RR 3.22, Po0.0001), and INSS stage (RR for stage 4 ¼ 6.21, Po0.0001). In addition, tumors expressing the c-kit receptor had a significantly lower recurrence rate than c-kit-negative tumors (RR 0.18, Po0.0001, Figure 2a) . Interestingly, one recurrence of a c-kit-positive poorly differentiated neuroblastoma presented as ganglioneuroblastoma of the intermixed type, which is known to have an excellent prognosis. This observation further supports the idea that c-kit expression is associated with a tendency towards differentiation.
Moreover, c-kit expression significantly identified subsets with good prognosis in both age groups (p1.5 and 41.5 years), in INSS stages 3, 4, and 4S, in tumors with INPC favorable and unfavorable histology, and in tumors with a single MYCN gene copy (Table 2) . Notably, no events occurred in c-kit-positive 4S tumors, whereas the probability for EFS in 4S tumors without ckit expression was only 56712% (Figure 2b ). In INSS stages 1 and 2, and in tumors with MYCN amplification, c-kit expression denoted a mere trend towards a better outcome.
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Owing to the latter observation, we wished to investigate the effects of an interaction between c-kit and MYCN. We found that the prognosis was excellent in c-kit-positive cases with a single MYCN gene copy, intermediate in tumors with either loss of c-kit expression or MYCN amplification, and dismal in tumors with concurrent MYCN amplification and c-kit negativity (Po0.0001, Figure 1c) .
When additional subgroups were formed on the basis of stage, patient age and MYCN status, it emerged that c-kit provided prognostic information for stage 4 patients diagnosed after 1 year of age (P ¼ 0.031), and tumors without MYCN amplification in the same group (P ¼ 0.009). In stage 4S tumors without MYCN amplification, the correlation between c-kit expression and EFS barely approached statistical significance (P ¼ 0.052).
We further compared all prognostically significant factors in multivariate regression analyses of the entire cohort and of the 132 cases without pretreatment. In Figure 1 Immunohistochemical reaction in two cases of poorly differentiated neuroblastoma, one c-kit positive (a) and the other c-kit negative (b). An example of quantitative RT-PCR for c-kit mRNA (top) and parallel Western blot analysis of c-kit protein expression (bottom) in nine consecutive neuroblastoma cases is shown in (c). In the top panel, bold lines correspond to dilutions of a GIST sample used as reference. Two immunopositive tumors (tumors #9 and #7, the latter being illustrated in (a)) contain high numbers of c-kit mRNA transcripts and display a strong signal in the Western blot. The remainder, classified as immunonegative, contains at least 10-fold lower levels of c-kit mRNA; no protein product of c-kit is detected by Western blotting c-kit and neuroblastoma prognosis M Krams et al these models, INSS stage 4 and loss of c-kit expression emerged as the leading independent predictors of adverse outcome, followed by MYCN amplification, which was nevertheless associated with a markedly lower relative risk. INPC grade and patient age were not selected as independent prognostic factors. The results are detailed in Table 3 . Treatment modalities were not selected as an independent prognostic factor in the multivariate analysis, nor did the inclusion of this covariate change the results of the multivariate models.
Discussion
The reported prevalence of c-kit in neuroblastomas ranges from 0 to 100% (Cohen et al., 1994; Beck et al., 1995; Timeus et al., 1997) , which is likely attributable to the analysis of different sample types (native tumors and cell lines), and to the use of different techniques. Since we were chiefly interested in protein expression, we opted for the immunohistochemical detection method. We used the polyclonal antiserum A4502 (DAKO), which showed consistent performance with low background in a previous investigation , a quality that was also appreciated by other investigators (Hornick and Fletcher, 2002) . By this approach, we detected the c-kit protein product in approximately 30% of our archival neuroblastoma samples.
The specificity of the immunoreaction was verified by quantitative RT-PCR for c-kit mRNA and Western blotting. Given the negative reaction in Western blots, the presence of low levels of c-kit mRNA in a number of immunonegative tumors may signify either a higher sensitivity of the RT-PCR method, or an early transcription before the onset of translation. Since mutations of the c-kit gene, the majority of which occur as deletions or insertions in exon 11, account for a constitutive overexpression of the protein in certain tumors (Hirota, 2001 ), we performed a screening for such mutations by the PCR of genomic DNA and subsequent capillary electrophoresis. No deletions or insertions were detected in either immunopositive or immunonegative tumor samples, indicating that mutations are unlikely to account for c-kit expression or its absence in neuroblastomas.
Taken together, our observations indicate that c-kit expression is transcriptionally regulated in neuroblastomas. Moreover, the frequent finding of diffusely cytoplasmic immunolabeling suggests an internalization of the receptor upon ligand binding (Jahn et al., 2002) . These findings point to a physiological regulation of the expression and the function of the c-kit receptor. Figure 2 Kaplan-Meier analysis of EFS in relation to c-kit expression in the entire cohort (a) and in stage 4S patients (b). In addition to c-kit, the biological behavior of neuroblastomas is modulated by the MYCN status (sc, single copy; amp, amplified 4five copies) (c) c-kit and neuroblastoma prognosis M Krams et al
Analysis of the EFS probabilities revealed a markedly better outcome in tumors that expressed c-kit compared with those that did not. This result was not expected given that, in various tumor types, c-kit is associated with malignancy. In myeloid leukemias, mast cell disorders, and gastrointestinal stromal tumors, different gain-of-function mutations in the c-kit gene, all resulting in constitutive tyrosine kinase activity, are considered to play a central role in oncogenesis and sustained tumor growth. In small-cell lung cancer, coexpression of c-kit and its ligand appears to result in an autocrine growth loop sustaining tumor cell proliferation (DiPaola et al., 1997) .
An analogous loop mechanism has been described in neuroblastoma cell lines (Cohen et al., 1994) . Although addition of SCF to the culture medium failed to further enhance the proliferative activity in these cells, antibody-mediated blockade of the receptor resulted in decreased growth and increased apoptosis. Our observations nevertheless suggest that in vitro data do not necessarily reflect the situation in vivo. Indeed, c-kit may exert divergent functions depending on a modulation by milieu factors and differential interactions with intracellular effector pathways (Kapur et al., 2001) , and alternative splicing of c-kit mRNA may elicit opposite effects (Caruana et al., 1999) . Moreover, no comparative information concerning the biological behavior of neuroblasts with and without c-kit expression can be derived from these data (Cohen et al., 1994) .
In our series of neuroblastomas, c-kit expression was intimately associated with the degree of differentiation, which is likely to account for its impact on prognosis. The propensity for differentiation is a unique trait of neuroblastoma, and a critical determinant of its biological behavior. It has therefore been postulated that the differentiation potential separates embryonal forms of neuroblastoma from true aggressive neoplasms (Hiyama et al., 1995) . In this regard, our results suggest that c-kit may be an indicator of earliest differentiation stages, even before the appearance of the corresponding morphological signs, as shown by a small proportion of positive cases among undifferentiated and poorly differentiated neuroblastomas (Table 1) .
These observations permit several interpretations. First, it is conceivable that c-kit induces differentiation in neuroblasts. This would be in keeping with the requirement of c-kit for the development of a Cajal cell phenotype in smooth muscle cells (Torihashi et al., 1999) . In this process, the proliferative stimulus in response to SCF (Cohen et al., 1994 ) may be transient, or downstream effectors such as Socs1 may switch the signaling pathway towards long-term survival and maturation (Keller et al., 1995; De Sepulveda et al., 1999) .
Alternatively, c-kit expression may follow the onset of differentiation, in analogy to its appearance during the development of the central nervous system (Ida et al., 1993) . This idea would be supported by the observation that the differentiating agent retinoic acid is able to bring about c-kit expression in various cell types (Hayashi et al., 1995) . Interestingly, in the central nervous system, c-kit induction is associated with neurite outgrowth (Hirata et al., 1993) and responsiveness to nerve growth factor (NGF). As the high-affinity NGF receptor encoded by the trkA gene (Nakagawara It is further tempting to envision for c-kit a regulation similar to that occurring in another type of neural crestderived cells, the melanocytes. During migration and maturation of their precursors, sequential stage-dependent c-kit expression is associated with different functional aspects. It is retained in normal epidermal melanocytes, but progressively lost in malignant melanomas as they become invasive and eventually acquire metastatic potential (Montone et al., 1997) . This loss of gene expression appears to be attributable to a deficiency in the transcription factor AP-2. Transfection of the kit gene into cell lines established from metastatic melanomas brakes their proliferation and restores their apoptotic potential (Bar-Eli, 2001 ). Since other tissues also lose c-kit along with malignant tranformation, it was proposed that c-kit is frequently involved in morphogenesis and differentiation, and is, therefore, negatively selected in the course of tumor progression (Natali et al., 1992) .
If a similar phenomenon was verified in neuroblastomas, c-kit expression might identify a subset of tumors that retain the properties of embryonal neural tissue, while loss of the antigen might indicate the acquisition of genuinely malignant potential. In vitro investigations designed to corroborate these data and to elucidate the biological basis of c-kit expression are underway. It is hoped that novel therapeutic approaches, for example, an exogenous induction of c-kit or its stimulation by recombinant SCF, may be derived from the expected findings.
